Free Trial
NYSEAMERICAN:OSTX

OS Therapies Q2 2026 Earnings Results & Report

OS Therapies logo
$1.41 +0.02 (+1.44%)
Closing price 04:10 PM Eastern
Extended Trading
$1.42 +0.01 (+0.78%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OS Therapies reported Q2 2026 earnings on August 14, 2026. The company reported EPS of -$0.20.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

OS Therapies EPS Results

Actual EPS
-$0.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OS Therapies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OS Therapies Q2 2026 Earnings FAQ

OS Therapies (NYSEAMERICAN:OSTX) reported earnings of -$0.20 per share for Q2 2026. The report was announced on Friday, August 14, 2026.

OS Therapies Earnings Headlines

The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
See More OS Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email.

About OS Therapies

OS Therapies (NYSEAMERICAN:OSTX), Inc. is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma and other solid tumors. The company’s work is directed toward cancer patients who have limited treatment options, with an emphasis on pediatric and young-adult oncology.

OS Therapies’ lead investigational product is OST-HER2, an immunotherapy designed to stimulate the immune system to recognize and attack tumors that express the HER2 protein. The therapy is being developed primarily for osteosarcoma, a rare bone cancer, and remains investigational rather than an approved commercial treatment.

The company’s activities include clinical development, oncology research and the advancement of additional potential therapies for solid tumors. OS Therapies is headquartered in the United States and has focused its development efforts on addressing significant unmet needs in cancer care.

View OS Therapies Profile